Identification of an Intravenous Injectable NK1 Receptor Antagonist for Use in Traumatic Brain Injury.

Area of Science:

• Neuroscience
• Pharmacology
• Trauma Research

Background:

• Traumatic brain injuries (TBI) are a major cause of death and disability.
• Moderate-to-severe TBI often leads to blood-brain barrier (BBB) dysfunction, cerebral edema, and neuroinflammation.
• Tachykinin NK1 receptor antagonists are being explored for TBI treatment.

Purpose of the Study:

• To identify and evaluate EUC-001, a novel selective NK1 receptor antagonist, as a potential therapeutic agent for TBI.
• To assess the efficacy of EUC-001 in preclinical models of TBI.

Main Methods:

• Characterization of EUC-001's affinity for the human NK1 receptor and its pharmacokinetic properties (solubility, CNS penetration).
• Administration of EUC-001 post-injury in an animal model of TBI.
• Assessment of BBB function, cerebral edema, mortality rates, and functional deficits (motor and cognitive).

Main Results:

• EUC-001 demonstrated high affinity for the NK1 receptor and favorable properties for intravenous administration and CNS penetration.
• Post-injury EUC-001 treatment dose-dependently restored BBB function and reduced cerebral edema.
• EUC-001 significantly decreased mortality and ameliorated both motor and cognitive functional deficits following TBI.

Conclusions:

• EUC-001 is a potent and selective NK1 antagonist with demonstrated efficacy in a preclinical TBI model.
• EUC-001 effectively mitigates key pathological consequences of TBI, including BBB dysfunction, cerebral edema, and functional impairments.
• EUC-001 represents a promising clinical candidate for the development of a novel TBI therapy.